LSV Asset Management Buys 807,215 Shares of Pfizer Inc. (NYSE:PFE)

LSV Asset Management boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,752,492 shares of the biopharmaceutical company's stock after buying an additional 807,215 shares during the quarter. Pfizer makes up about 0.8% of LSV Asset Management's holdings, making the stock its 22nd biggest position. LSV Asset Management owned about 0.24% of Pfizer worth $364,854,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC boosted its position in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after buying an additional 2,923,537 shares during the last quarter. Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter worth about $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.14 during mid-day trading on Monday, reaching $22.05. The company had a trading volume of 26,674,615 shares, compared to its average volume of 40,187,113. The company has a 50-day moving average price of $25.25 and a two-hundred day moving average price of $26.38. The stock has a market cap of $125.06 billion, a PE ratio of 15.64, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the company posted $0.10 EPS. The company's quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.